Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
BMC Infect Dis ; 16(1): 587, 2016 Oct 20.
Artículo en Inglés | MEDLINE | ID: mdl-27765017

RESUMEN

BACKGROUND: Neonatal infection constitutes one of Senegal's most important public health problems, with a mortality rate of 41 deaths per 1,000 live births. METHODS: Between January 2007 and March 2008, 242 neonates with suspected infection were recruited at three neonatal intensive care units in three major tertiary care centers in Dakar, the capital of Senegal. Neonatal infections were confirmed by positive bacterial blood or cerebrospinal fluid culture. The microbiological pattern of neonatal infections and the antibiotic susceptibility of the isolates were characterized. In addition, the genetic basis for antibiotic resistance and the genetic background of third-generation cephalosporin-resistant (3GC-R) Enterobacteriaceae were studied. RESULTS: A bacteriological infection was confirmed in 36.4 % (88/242) of neonates: 22.7 % (30/132) during the early-onset and 52.7 % (58/110) during the late-onset periods (p > 0.20). Group B streptococci accounted for 6.8 % of the 88 collected bacterial isolates, while most of them were Enterobacteriaceae (n = 69, 78.4 %). Of these, 55/69 (79.7 %) were 3GC-R. The bla CTX-M-15 allele, the bla SHV and the bla TEM were highly prevalent (63.5, 65.4 and 53.8 %, respectively), usually associated with qnr genes (65.4 %). Clonally related strains of 3GC-R Klebsiella pneumoniae and 3GC-R Enterobacter cloacae, the two most commonly recovered 3GC-R Enterobacteriaceae (48/55), were detected at the three hospitals, underlining the role of cross-transmission in their spread. The overall case fatality rate was 18.6 %. CONCLUSIONS: Measures should be taken to prevent nosocomial infections and the selection of resistant bacteria.


Asunto(s)
Cefalosporinas/farmacología , Infecciones por Enterobacteriaceae/microbiología , Enterobacteriaceae/efectos de los fármacos , Resistencia betalactámica/efectos de los fármacos , Enterobacter cloacae/efectos de los fármacos , Enterobacter cloacae/aislamiento & purificación , Enterobacter cloacae/patogenicidad , Enterobacteriaceae/aislamiento & purificación , Enterobacteriaceae/patogenicidad , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Infecciones por Enterobacteriaceae/epidemiología , Femenino , Humanos , Recién Nacido , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/aislamiento & purificación , Klebsiella pneumoniae/patogenicidad , Masculino , Pruebas de Sensibilidad Microbiana , Senegal/epidemiología , Centros de Atención Terciaria , Resultado del Tratamiento , Resistencia betalactámica/genética , beta-Lactamasas/genética
2.
Mycopathologia ; 174(4): 331-4, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22565488

RESUMEN

We carried out a soil sampling survey in September 2008 in central Cayenne, French Guiana, using molecular methods to assess the presence of the dimorphic fungus Histoplasma capsulatum. Four of the 31 samples collected (12.9 %) tested positive by PCR, with confirmation of the result by DNA sequencing. H. capsulatum is therefore present in urban environments in French Guiana. These results provide additional support for the primary prophylaxis of AIDS-related histoplasmosis in French Guiana.


Asunto(s)
Monitoreo del Ambiente , Histoplasma/aislamiento & purificación , Microbiología del Suelo , Guyana Francesa , Histoplasma/genética
3.
J Clin Microbiol ; 49(6): 2304-6, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21490186

RESUMEN

Clavispora lusitaniae is an opportunistic human pathogen responsible for 0.6 to 2% of candidemia. This species is intrinsically susceptible to echinocandins. Nevertheless, in this study, development of echinocandin resistance in C. lusitaniae isolates was observed during caspofungin treatment. This resistance resulted from missense mutation in the echinocandin target Fks1 gene.


Asunto(s)
Antifúngicos/farmacología , Farmacorresistencia Fúngica , Equinocandinas/farmacología , Micosis/tratamiento farmacológico , Micosis/microbiología , Saccharomycetales/efectos de los fármacos , Anciano , Sustitución de Aminoácidos/genética , Antifúngicos/administración & dosificación , Caspofungina , Análisis Mutacional de ADN , ADN de Hongos/química , ADN de Hongos/genética , Equinocandinas/administración & dosificación , Glucosiltransferasas/genética , Humanos , Lipopéptidos , Masculino , Datos de Secuencia Molecular , Mutación Missense , Análisis de Secuencia de ADN
4.
Microbiol Spectr ; 9(2): e0113821, 2021 10 31.
Artículo en Inglés | MEDLINE | ID: mdl-34668768

RESUMEN

The aim of this study was to evaluate diagnostic means, host factors, delay of occurrence, and outcome of patients with COVID-19 pneumonia and fungal coinfections in the intensive care unit (ICU). From 1 February to 31 May 2020, we anonymously recorded COVID-19-associated pulmonary aspergillosis (CAPA), fungemia (CA-fungemia), and pneumocystosis (CA-PCP) from 36 centers, including results on fungal biomarkers in respiratory specimens and serum. We collected data from 154 episodes of CAPA, 81 of CA-fungemia, 17 of CA-PCP, and 5 of other mold infections from 244 patients (male/female [M/F] ratio = 3.5; mean age, 64.7 ± 10.8 years). CA-PCP occurred first after ICU admission (median, 1 day; interquartile range [IQR], 0 to 3 days), followed by CAPA (9 days; IQR, 5 to 13 days), and then CA-fungemia (16 days; IQR, 12 to 23 days) (P < 10-4). For CAPA, the presence of several mycological criteria was associated with death (P < 10-4). Serum galactomannan was rarely positive (<20%). The mortality rates were 76.7% (23/30) in patients with host factors for invasive fungal disease, 45.2% (14/31) in those with a preexisting pulmonary condition, and 36.6% (34/93) in the remaining patients (P = 0.001). Antimold treatment did not alter prognosis (P = 0.370). Candida albicans was responsible for 59.3% of CA-fungemias, with a global mortality of 45.7%. For CA-PCP, 58.8% of the episodes occurred in patients with known host factors of PCP, and the mortality rate was 29.5%. CAPA may be in part hospital acquired and could benefit from antifungal prescription at the first positive biomarker result. CA-fungemia appeared linked to ICU stay without COVID-19 specificity, while CA-PCP may not really be a concern in the ICU. Improved diagnostic strategy for fungal markers in ICU patients with COVID-19 should support these hypotheses. IMPORTANCE To diagnose fungal coinfections in patients with COVID-19 in the intensive care unit, it is necessary to implement the correct treatment and to prevent them if possible. For COVID-19-associated pulmonary aspergillosis (CAPA), respiratory specimens remain the best approach since serum biomarkers are rarely positive. Timing of occurrence suggests that CAPA could be hospital acquired. The associated mortality varies from 36.6% to 76.7% when no host factors or host factors of invasive fungal diseases are present, respectively. Fungemias occurred after 2 weeks in ICUs and are associated with a mortality rate of 45.7%. Candida albicans is the first yeast species recovered, with no specificity linked to COVID-19. Pneumocystosis was mainly found in patients with known immunodepression. The diagnosis occurred at the entry in ICUs and not afterwards, suggesting that if Pneumocystis jirovecii plays a role, it is upstream of the hospitalization in the ICU.


Asunto(s)
COVID-19/epidemiología , Coinfección/mortalidad , Fungemia/epidemiología , Neumonía por Pneumocystis/epidemiología , Aspergilosis Pulmonar/epidemiología , Anciano , Antifúngicos/uso terapéutico , COVID-19/mortalidad , COVID-19/patología , Coinfección/epidemiología , Cuidados Críticos , Femenino , Francia/epidemiología , Fungemia/tratamiento farmacológico , Fungemia/mortalidad , Galactosa/análogos & derivados , Galactosa/sangre , Humanos , Unidades de Cuidados Intensivos/estadística & datos numéricos , Masculino , Mananos/sangre , Persona de Mediana Edad , Neumonía por Pneumocystis/tratamiento farmacológico , Neumonía por Pneumocystis/mortalidad , Aspergilosis Pulmonar/tratamiento farmacológico , Aspergilosis Pulmonar/mortalidad , Estudios Retrospectivos , SARS-CoV-2 , Resultado del Tratamiento
6.
Adv Respir Med ; 2018 Sep 02.
Artículo en Inglés | MEDLINE | ID: mdl-30173411

RESUMEN

INTRODUCTION: We studied the characteristics of the screening procedure for alpha-1 antitrypsin at Nevers Hospital (France), together with the performance of serum protein gel electrophoresis for the fortuitous detection of patients with deficiency. MATERIAL AND METHODS: We carried out a retrospective study of requests for alpha-1 antitrypsin determination referred to the laboratory during 3 years. We compared these requests with the numbers of patients seen at the hospital and requiring screening according to international recommendations. In parallel, we reviewed all the serum protein gel electrophoresis results obtained during the same period. RESULTS: The laboratory received 102 direct requests for alpha-1 antitrypsin determination, whereas more than 1397 patients presented an indication for screening. No case of alpha-1 antitrypsin deficiency was detected among the 102 patients screened. In parallel, 5551 serum protein gel electrophoresis analyses were carried out at the laboratory. A decrease in the size of the alpha-1 globulin fraction was detected in 68 patients. Seventeen of these patients underwent alpha-1 antitrypsin determinations and 14 were found to have alpha-1 antitrypsin deficiency. CONCLUSION: Alpha-1 antitrypsin deficiency was more frequently detected fortuitously, by electrophoresis, than through efficient screening. The exploration of alpha-1 globulin deficiencies by serum protein gel electrophoresis thus appears to be still a particularly efficient approach to the detection of alpha-1 antitrypsin deficiency and should be carried out systematically. Furthermore, the testing of all patients with an indication for screening according to international recommendations should be encouraged.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA